At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Erchonia CFL Laserdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of the Effect of the Erchonia Corporation CFL Laser for Non-invasive Reduction of Submental Fat
In Brief
A clinical study evaluating Erchonia CFL Laser for Weight Loss. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® CFL (manufactured by Erchonia Corporation (the Company), in providing noninvasive fat reduction in the submental area.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWeight Loss
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartJul 2023
First PostedJul 2023
Primary CompletionMay 2024
Study CompletionSep 2024
TodayJul 2026
First PostedJul 20, 2023
Enrollment StartJul 12, 2023
Primary CompletionMay 31, 2024
Study CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.9 years ago
Interventions
Erchonia CFL Laserdevice
405nm violet and 520nm green laser light therapy.